Pusan National University Hospital

Nelonemdaz Shows Promise in Treating Out-of-Hospital Cardiac Arrest Patients

4 months ago

A recent clinical trial has highlighted the potential of Nelonemdaz in treating patients who have suffered out-of-hospital cardiac arrest. The study, supported by the Ministry of Health and Welfare of the Republic of Korea and GNT Pharma, involved multiple institutions and adhered to strict ethical guidelines, offering new hope for improving survival and recovery outcomes.

Pharos iBio's PHI-101 Demonstrates Promising Complete Response in AML Phase 1 Trial

7 months ago

• Pharos iBio's PHI-101, a first-in-class treatment for acute myeloid leukemia (AML), achieved a 50% overall complete response rate in a Phase 1 study. • The study included patients who relapsed or failed after prior FLT3 inhibitor therapy, with 75% falling into this category, highlighting PHI-101's potential. • Pharos iBio plans to complete Phase 1 and file an IND application for a global Phase 2 trial, aiming for early commercialization via conditional marketing authorization. • Data from the expanded Phase 1b study of PHI-101-AML will be presented at the American Society of Hematology (ASH) Annual Meeting in December.